Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.560
-0.070 (-4.29%)
At close: Aug 21, 2026, 4:00 PM EDT
1.580
+0.020 (1.28%)
After-hours: Aug 21, 2026, 7:50 PM EDT
Alzamend Neuro Employees
As of April 30, 2026, Alzamend Neuro had 6 total employees, including 4 full-time and 2 part-time employees. The number of employees decreased by 1 or -14.29% compared to the previous year.
Employees
6
Change
-1
Growth
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$1,462,064
Market Cap
7.47M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Apr 30, 2026 | 6 | -1 | -14.29% | 4 | 2 |
| Jan 31, 2026 | 6 | -1 | -14.29% | 4 | 2 |
| Oct 31, 2025 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2025 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2025 | 7 | 0 | - | 4 | 3 |
| Jan 31, 2025 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2024 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2024 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2024 | 7 | 0 | - | 4 | 3 |
| Jan 31, 2024 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2023 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Apr 30, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Jan 31, 2023 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2022 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Apr 30, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Jan 31, 2022 | 7 | 3 | 75.00% | 3 | 4 |
| Oct 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bolt Biotherapeutics | 23 |
| AIM ImmunoTech | 21 |
| Azitra | 13 |
| Aprea Therapeutics | 8 |
| Ernexa Therapeutics | 7 |
| Immuron | 7 |
| Traws Pharma | 7 |
| Can-Fite BioPharma | 5 |
ALZN News
- 1 day ago - Alzamend Neuro registers to sell 98.39M shares of common stock for holders - TheFly
- 2 days ago - Alzamend Neuro Registration statement: Registration filing - Filings
- 3 days ago - Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC - PRNewsWire
- 5 days ago - Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain - PRNewsWire
- 19 days ago - Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending - PRNewsWire
- 4 weeks ago - Alzamend Neuro Annual report: Q4 2026 - Filings
- 4 weeks ago - Alzamend Neuro Slides: Corporate presentation - Filings
- 4 months ago - Alzamend Neuro’s AL001 shows “encouraging” data in Phase II brain trial - TheFly